• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Vigil Neuroscience Inc.

    8/5/25 5:03:37 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VIGL alert in real time by email
    POS AM 1 d895219dposam.htm POS AM POS AM

    As filed with the Securities and Exchange Commission on August 5, 2025

    Registration No. 333-270710

    Registration No. 333-286243

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT TO

    FORM S-3 REGISTRATION STATEMENT NO. 333-270710

    FORM S-3 REGISTRATION STATEMENT NO. 333-286243

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    VIGIL NEUROSCIENCE, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Delaware  

    100 Forge Road, Suite 700

    Watertown, Massachusetts 02472

    (857) 254-4445

      85-1880494

    (State or other jurisdiction of

    incorporation or organization)

     

    (Address, including zip code, and telephone number,

    including area code, of registrant’s principal
    executive offices)

     

    (I.R.S. Employer

    Identification Number)

     

     

    Ivana Magovčević-Liebisch

    Chief Executive Officer

    Vigil Neuroscience, Inc.

    100 Forge Road, Suite 700

    Watertown, Massachusetts 02472

    (857) 254-4445

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Kingsley L. Taft, Esq.

    Jacqueline Mercier, Esq.

    Gabriela Morales-Rivera, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, MA 02210

    (617) 570-1000

     

     

    Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statement.

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

     

     
     


    DEREGISTRATION OF SECURITIES

    These Post-Effective Amendments (the “Post-Effective Amendments”) relate to the following registration statements on Form S-3 (together, the “Registration Statements”), filed with the Securities and Exchange Commission (the “SEC”) by Vigil Neuroscience, Inc., a Delaware corporation (the “Registrant”):

     

      •  

    Registration Statement No.  333-270710, registering shares of common stock, par value $0.0001 per share (“Common Stock”), of the Registrant, shares of preferred stock, par value $0.0001 per share (“Preferred Stock”), of the Registrant, debt securities, warrants, and units, which was filed with the SEC on March 21, 2023; and

     

      •  

    Registration Statement No.  333-286243, registering the offer and resale of up to an aggregate of 5,376,340 shares of Common Stock by the selling stockholder identified in the Registration Statement, issuable upon the conversion of 537,634 shares of Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (“Series A Non-Voting Convertible Preferred Stock”), which was filed with the SEC on March 31, 2025.

    On August 5, 2025, pursuant to the terms of the Agreement and Plan of Merger (the “Merger Agreement”), dated as of May 21, 2025, by and among the Registrant, Sanofi, a French société anonyme (“Sanofi”), and Vesper Acquisition Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Sanofi (“Merger Sub”), Merger Sub merged with and into the Registrant (the “Merger”), with the Registrant surviving the Merger as a wholly-owned subsidiary of Sanofi.

    As a result of the Merger, the Registrant has terminated, as of the date hereof, any and all offerings of its securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. In accordance with an undertaking made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unissued at the termination of the offerings, by filing these Post-Effective Amendments, the Registrant hereby removes from registration all securities registered but unsold under such Registration Statements, if any, as of the date hereof, and the Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Massachusetts, on August 5, 2025.

     

    VIGIL NEUROSCIENCE, INC.
    By:   /s/ Michael Tolpa
      Name: Michael Tolpa
      Title: Treasurer

    No other person is required to sign these Post-Effective Amendments to the Registration Statements on Form S-3 in reliance on Rule 478 of the Securities Act of 1933, as amended.

    Get the next $VIGL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VIGL

    DatePrice TargetRatingAnalyst
    5/28/2025$8.00Buy → Hold
    Stifel
    12/4/2024Outperform
    William Blair
    12/19/2023$13.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    10/18/2023$23.00Mkt Outperform
    JMP Securities
    3/31/2023$15.00Buy
    Mizuho
    9/16/2022$19.00Outperform
    Wedbush
    8/29/2022$24.00Buy
    H.C. Wainwright
    2/1/2022$17.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $VIGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Atlas Venture Fund Xii, L.P. returned 5,836,874 shares to the company (SEC Form 4)

    4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

    8/7/25 5:00:10 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Thistle Mary returned 5,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

    8/5/25 10:01:18 AM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Medical Officer Kaufmann Petra

    4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

    8/5/25 10:00:33 AM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vigil Neuroscience downgraded by Stifel with a new price target

    Stifel downgraded Vigil Neuroscience from Buy to Hold and set a new price target of $8.00

    5/28/25 8:11:47 AM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    William Blair initiated coverage on Vigil Neuroscience

    William Blair initiated coverage of Vigil Neuroscience with a rating of Outperform

    12/4/24 7:51:48 AM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vigil Neuroscience downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Vigil Neuroscience from Equal-Weight to Underweight and set a new price target of $4.00 from $13.00 previously

    12/19/23 7:39:43 AM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

    WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on the Phase 2 IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). Iluzanebart demonstrated a favorable safety, tolerability and pharmacokinetic profile across both the 20 mg/kg and 40 mg/kg dose cohorts. The Phase 2 IGNITE trial showed no beneficial effects on biomarker or clinical effica

    6/4/25 7:00:00 AM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

    - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

    5/21/25 7:30:46 PM ET
    $SNY
    $VIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

    – On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2025, and provided updates on its recent progress. "During the quarter, we continued to make meaningful progress across our two TREM2 programs, VG-3927 and iluzanebart," said Ivana Ma

    5/7/25 7:00:00 AM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Budd Haeberlein Samantha L. bought $20,520 worth of shares (12,000 units at $1.71) (SEC Form 4)

    4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

    12/19/24 6:44:11 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Magovcevic-Liebisch Ivana bought $8,400 worth of shares (5,000 units at $1.68), increasing direct ownership by 2% to 222,687 units (SEC Form 4)

    4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

    12/19/24 6:42:45 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Magovcevic-Liebisch Ivana bought $8,350 worth of Common Stock (5,000 units at $1.67), increasing direct ownership by 2% to 217,687 units (SEC Form 4)

    4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)

    12/18/24 5:51:48 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIGL
    SEC Filings

    View All

    SEC Form 15-12G filed by Vigil Neuroscience Inc.

    15-12G - Vigil Neuroscience, Inc. (0001827087) (Filer)

    8/15/25 7:38:48 AM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Vigil Neuroscience Inc.

    SCHEDULE 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

    8/14/25 4:07:04 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Vigil Neuroscience Inc.

    SCHEDULE 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

    8/14/25 1:45:23 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIGL
    Leadership Updates

    Live Leadership Updates

    View All

    Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic

    Augustine Therapeutics appoints Gerhard Koenigas Chief Executive Officer as Company Prepares to Enter the Clinic Industry veteran Gerhard Koenig, PhD, current Executive Chairman, appointed as CEOBest-in-class highly selective HDAC6 inhibitor pioneer for disease-modifying treatment of neuromuscular, neurodegenerative and cardiometabolic diseases poised to enter the clinic LEUVEN, Belgium – February 13, 2025 – Augustine Therapeutics ("Augustine" or "the Company"), a preclinical-stage biotechnology company focused on innovative therapies for neuromuscular, neurodegenerative and cardiometabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, today announc

    2/13/25 7:00:00 AM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases

    Proceeds will advance lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 study Gerhard Koenig appointed as executive chairman of Augustine's Board of Directors Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gem

    6/26/24 1:00:00 AM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

    – Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer's disease ongoing; Interim data analysis on track for mid-2024 – WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent progress. "During the quarter, we continued to progress iluzanebart, our monoclonal antibody, and VG-3927, our or

    5/7/24 4:05:00 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIGL
    Financials

    Live finance-specific insights

    View All

    Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

    - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

    5/21/25 7:30:46 PM ET
    $SNY
    $VIGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

    VGL101 demonstrated favorable safety, tolerability and PK profiles in single ascending dose and multiple ascending dose cohortsVGL101 achieved dose dependent, robust and durable decreases in CSF sTREM2 demonstrating proof of target engagement further validating its mechanism of action On track to initiate Phase 2 trial with a 20 mg/kg dose of VGL101 in ALSP patients this quarterCompany to host conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced interim topline r

    11/2/22 7:00:00 AM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VIGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vigil Neuroscience Inc.

    SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

    11/14/24 4:19:18 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vigil Neuroscience Inc.

    SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

    11/14/24 10:00:07 AM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Vigil Neuroscience Inc.

    SC 13D/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

    10/9/24 6:22:58 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care